WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Scenery of Zanda county, SW China's Tibet
Exhibition featuring marine civilization of South China Sea held at Hainan Museum
An Overview of Xi's Diplomacy in Spring 2023
US, Mexico drop bid to host 2027 World Cup
Explore enchanting scenery of Xinjiang
This week: Retail sales, United Airlines and Netflix earnings
Zhongyuan Town in E China revitalized through economic transformation, upgrading
Queen Mary and King Frederik are caught in a royal Photoshop row
Xiplomacy: How China Helps Preserve Cultural Heritage Sites in Asia